Athena Athena

X

Find the latest Drugs in Development and Pipeline Prospector News of Pierre Fabre.

  • Webinars & Exhibitions

PharmaCompass
Send me more info on How To Grow My Bussiness Digitally?
Pierre Fabre
France Flag
Country
Country
France
Address
Address
3, Avenue Hubert Curien Toulouse, Occitanie 31100
Telephone
Telephone
+33 5 63 62 38 50

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Details:

The companies will work to seek the regulatory approval for Foundation Medicine assays which detect mutations including BRAFV600E to identify patients for potential treatment with Pierre’s BRAF/MEK inhibitor, BRAFTOVI (encorafenib) and MEKTOVI (binimetinib), in the EU.


Lead Product(s): Encorafenib,Binimetinib

Therapeutic Area: Oncology Product Name: Braftovi

Highest Development Status: Phase IIIProduct Type: Small molecule

Recipient: Foundation Medicine

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 15, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Braftovi (encorafenib) + Mektovi (binimetinib) is approved for the treatment of adult patients with BRAFV600-mutant advanced non-small cell lung cancer (NSCLC), who are either treatment naïve or have received prior therapy.


Lead Product(s): Encorafenib,Binimetinib

Therapeutic Area: Oncology Product Name: Braftovi

Highest Development Status: ApprovedProduct Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable November 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the agreement, Pierre Fabre gains U.S. and remaining global commercial markets for tab-cel (tabelecleucel), an allogeneic Epstein-Barr virus (EBV)-specific T-cell immunotherapy.


Lead Product(s): Tabelecleucel

Therapeutic Area: Infections and Infectious Diseases Product Name: Tab-cel

Highest Development Status: Phase IIIProduct Type: Cell and Gene therapy

Recipient: Atara Biotherapeutics

Deal Size: $640.0 million Upfront Cash: $30.0 million

Deal Type: Partnership November 01, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

STX-721, Scorpion's highly differentiated, orally bioavailable, irreversible highly selective tyrosine kinase inhibitor targeting EGFR and ERBB2 (HER2) Exon 20 insertion mutations, well-known, clinically validated oncogenic drivers in non-small cell lung cancer.


Lead Product(s): STX-721

Therapeutic Area: Oncology Product Name: STX-721

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Recipient: Scorpion Therapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable October 10, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the terms of the collaboration, Vernalis will use its expertise to enable drug discovery against an undisclosed portfolio of multiple oncology targets and use fragment and structure-based methods to identify small molecules that modulate their activity.


Lead Product(s): Undisclosed

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: DiscoveryProduct Type: Small molecule

Recipient: Vernalis

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration September 25, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The acquisition allows Pierre to add VERT-002 to its oncology discovery pipeline. VERT-002 is a monoclonal antibody, acting as a degrader of c-MET. This target is a known disease driver in patients suffering from NSCLC with mutations or amplification of MET.


Lead Product(s): VERT-002

Therapeutic Area: Oncology Product Name: VERT-002

Highest Development Status: IND EnablingProduct Type: Large molecule

Recipient: Vertical bio

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Acquisition September 12, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Terran obtains exclusive global development and commercialization rights for idazoxan hydrochloride, a selective alpha 2 receptor antagonist and a late-stage clinical therapeutic for the treatment of schizophrenia.


Lead Product(s): Idazoxan

Therapeutic Area: Psychiatry/Psychology Product Name: Undisclosed

Highest Development Status: Phase IIProduct Type: Small molecule

Partner/Sponsor/Collaborator: Terran Biosciences

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Licensing Agreement June 02, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Under the agreement, Scorpion will lead development of STX-721 and Pierre Fabre will lead development of STX-241. Scorpion will retain commercialization rights to STX-721 and STX-241 in US, Canada and Japan, and Pierre Fabre will retain commercialization in other territories.


Lead Product(s): STX-721

Therapeutic Area: Oncology Product Name: STX-721

Highest Development Status: IND EnablingProduct Type: Small molecule

Recipient: Scorpion Therapeutics

Deal Size: $618.0 million Upfront Cash: $65.0 million

Deal Type: Collaboration April 04, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

Ebvalloâ„¢ (tabelecleucel) is an allogeneic, EBV-specific T-cell immunotherapy which targets and eliminates EBV-infected cells in an HLA-restricted manner.


Lead Product(s): Tabelecleucel

Therapeutic Area: Infections and Infectious Diseases Product Name: Ebvallo

Highest Development Status: ApprovedProduct Type: Cell and Gene therapy

Partner/Sponsor/Collaborator: Atara Biotherapeutics

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable February 08, 2023

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content

Details:

The agreement will support a clinical proof-of-concept trial evaluating ERAS-007, an oral ERK1/2 inhibitor, in combination with encorafenib and the anti-EGFR antibody cetuximab for the treatment of patients with BRAF V600E-mutant metastatic colorectal cancer (mCRC).


Lead Product(s): ERAS-007,Encorafenib,Cetuximab

Therapeutic Area: Oncology Product Name: ERAS-007

Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule

Recipient: Erasca

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Collaboration November 30, 2022

ASK
US
PHARMACOMPASS
Upload
your Marketing & Sales content
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty
Post Enquiry
POST ENQUIRY